Apatinib was reported to suppress angiogenesis in anaplastic thyroid carcinoma by blocking the Akt/GSK3/ANG pathway (20–22); however, the effect of apatinib in PTC is unclear. The gene discussed is AKT1; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.